Novo Nordisk inked an obesity deal worth up to $2.2 billion on Wednesday, and sent shares of Septerna into the stratosphere.

Novo Nordisk announced it is partnering with telehealth platforms to offer its blockbuster drug Wegovy. The move will help it capture a large number of consumers who had flocked to digital health ...

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...

Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the ...

The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products ...

Novo Nordisk's Q1 results show a dramatic expansion in sales beyond the US. Nevertheless, issues remain, and its outlook for ...

6 May 2025 – Novo Nordisk today announced that new data spanning the company’s industry-leading portfolio across metabolic and cardiovascular health will be presented at the upcoming 32 nd ...

MONDAY, April 21, 2025 (HealthDay News) -- The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging ... The seized counterfeit products display a combination ...

Novo Nordisk NOVO.B3.59%increase; green up pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense ...

Health-care companies rose after strong earnings from one fast-growing company. Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations.